Contemporary progress in ovarian cancer screening.
Our limited understanding of the natural biology of ovarian cancer, along with its low prevalence in the general population make early detection especially challenging. To be successful at the population level, an ovarian cancer screening test must prove its beneficial effect on ovarian cancer-specific mortality while achieving near-perfect specificity in order to minimize the harms resulting from false-positive results. No current screening tests for ovarian cancer fulfill these expectations. We review the current status and the challenges of ovarian cancer screening in the context of evidence-based principles that define a valuable cancer screening program.
Walsh
Christine S
CS
Department of Obstetrics and Gynecology, University of California, Los Angeles, David Geffen School of Medicine at UCLA, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite 160W, Los Angeles, CA 90048, USA. walshc@cshs.org
Karlan
B Y
BY
D014408:Biomarkers, Tumor / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology / Q000517:prevention & control; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor